Dr Reddy's acquires Progynova trademarks for USD 32.15 mn, enters HRT segment

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹1282.90

prior close

₹1290.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-1.5%+1.1% vs market

Pharmaceuticals peers, median of 157sector-1.2%+0.8% vs sector

On the reaction day the stock moved 1.1 pts more than Nifty 100 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.2

15m

+0.1

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4-1.5+1.1-1.2+0.8

Next day

-0.4-1.0+0.6-1.4+1.0

+1.7-0.5+2.2-1.6+3.4

+1.3-1.4+2.7-2.1+3.4

+1.7-1.1+2.8-2.4+4.1

+2.6-1.0+3.6-2.0+4.5

+0.4-3.5+3.9-4.6+5.0

15d

+0.6-10.0+10.5-6.8+7.4

-0.2-10.7+10.5-7.5+7.2

-4.1-4.7+0.6+0.6-4.6

+4.0-7.4+11.4+3.2+0.8

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Dr. Reddy's has acquired the trademarks Progynova and Cyclo-Progynova and related assets for India from UK-based Mercury Pharma Group for USD 32.15 million. The deal marks Dr. Reddy's entry into the Hormone Replacement Therapy segment and strengthens its gynecology portfolio. Progynova is the number one brand in India's estradiol market, with about INR 100 crore in sales as per IQVIA MAT December 2025. The transaction is not a related party deal.

Likely market impact

Adds a market-leading HRT brand to portfolio, expanding gynaecology presence in India. Modest deal size, likely positive for growth.